Inflarx Stock Price, News & Analysis

InflaRx (IFRX) has announced its participation in three major investor conferences in June and July 2025. The company will present at the Jefferies Global Healthcare Conference on June 4th at 7:35 AM ET, participate in a dermatology panel at the Oppenheimer Innovators in I&I Summit on June 25th, and conduct one-on-one meetings at the Leerink Partners Therapeutics Forum on July 8th. InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics, developing treatments targeting the complement system. Their lead product, vilobelimab, is an intravenous anti-C5a monoclonal antibody, while INF904 is their oral small molecule C5a receptor inhibitor in development.

InflaRx (IFRX) reported Q1 2025 financial results and key business updates. The company maintains a strong financial position with €65.7 million in cash and equivalents as of March 31, 2025, providing runway into 2027. Key upcoming catalysts include an interim analysis for vilobelimab's Phase 3 trial in pyoderma gangrenosum (PG) expected in May-June 2025, and topline Phase 2a data for INF904 in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected in summer 2025. The company recently completed successful toxicology studies for INF904 and received EU marketing authorization for GOHIBIC (vilobelimab) for SARS-CoV-2-induced ARDS. Q1 2025 resulted in a net loss of €8.3 million (€0.13 per share), improved from €9.7 million loss in Q1 2024. In February 2025, InflaRx raised €28.7 million through a public offering.

InflaRx, a pioneering biopharmaceutical company listed on Nasdaq (IFRX), has announced it will release its first quarter 2025 financial and operating results on May 7, 2025, before market opening. No earnings call is scheduled.

The company specializes in developing anti-inflammatory therapeutics by targeting the complement system, specifically the C5a and C5aR pathways. Their flagship product, vilobelimab, is an intravenous first-in-class anti-C5a antibody that has shown promising clinical results across multiple indications. Additionally, they are developing INF904, an oral C5a receptor inhibitor.

Founded in 2007, InflaRx maintains offices in Jena and Munich, Germany, and Ann Arbor, Michigan, USA. The company operates through two wholly owned subsidiaries: InflaRx GmbH in Germany and InflaRx Pharmaceuticals in the USA.

InflaRx (IFRX) reported key achievements for 2024 and milestones for 2025. The company received European Commission approval for GOHIBIC® (vilobelimab) to treat SARS-CoV-2-induced ARDS. They reached a 30-patient recruitment milestone in Phase 3 vilobelimab trial for pyoderma gangrenosum, with interim analysis expected by May 2025.

Financial highlights include:

• Cash position of €55.2 million as of December 31, 2024
• Additional €28.7 million raised through public offering in February 2025
• Cash runway extended into 2027
• Net loss of €46.1 million (€0.78 per share) in 2024
• R&D expenses decreased to €35.4 million

The company dosed first patient in Phase 2a trial for oral C5aR inhibitor INF904, with topline data in chronic spontaneous urticaria and hidradenitis suppurativa expected in summer 2025. Multiple data presentations at AAD 2025 highlighted vilobelimab's potential in reducing systemic inflammation.

InflaRx (NASDAQ: IFRX) presented multiple data sets for vilobelimab at the 2025 AAD Annual Meeting, showcasing its potential in treating inflammatory conditions. The presentations included results from studies in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).

Key findings for PG showed vilobelimab was well-tolerated with mostly mild to moderate adverse events. The PK/PD data demonstrated approximately 90% reduction in C5a levels by Day 15, sustained through Day 99 in higher dose groups.

In HS, the Phase 2b SHINE trial revealed significant improvements:

• 63.2% reduction in draining tunnels versus 18.0% for placebo
• 40.9% complete resolution of draining tunnels versus 13.0% for placebo (3.1x improvement)
• 800mg vilobelimab significantly reduced C5a concentrations from Day 1
• Safety analysis showed the drug was well-tolerated across all doses

InflaRx N.V. (Nasdaq: IFRX) announced that all their submitted abstracts featuring vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS) have been accepted for presentation at the 2025 American Academy of Dermatology Annual Meeting in Orlando, FL.

The presentations include first-time data on reduction in draining tunnels with vilobelimab in HS patients, and insights on a modified HiSCR scoring system. The abstracts cover safety studies, pharmacokinetic/pharmacodynamic analyses, and efficacy data from Phase 2 trials in both PG and HS conditions.

Vilobelimab, a first-in-class monoclonal anti-human complement factor C5a antibody, is currently in Phase 3 trials for PG and has received orphan drug designation from both FDA and EMA, plus FDA fast track designation for PG treatment.

InflaRx (Nasdaq: IFRX), a biopharmaceutical company developing anti-inflammatory therapeutics targeting the complement system, will release its fourth quarter and full year 2024 financial results on March 20, 2025, without a conference call.

The company will participate in two upcoming investor conferences: the Leerink Global Healthcare Conference (March 9-12 in Miami Beach) featuring a fireside chat on March 10 at 10:40 AM ET, and the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, with a virtual fireside chat at 8:30 AM ET. Both events will include one-on-one investor meetings.

InflaRx specializes in developing inhibitors of the complement activation factor C5a and its receptor C5aR. Their lead product candidate is vilobelimab, an intravenous anti-C5a monoclonal antibody, and they're also developing INF904, an oral C5a receptor inhibitor.

InflaRx (Nasdaq: IFRX) has completed its underwritten public offering, raising approximately $30 million in gross proceeds. The offering consisted of 8,250,000 ordinary shares priced at $2.00 per share and pre-funded warrants to purchase up to 6,750,000 ordinary shares. The pre-funded warrants were priced at $1.999 each, with an exercise price of $0.001.

The company has granted underwriters a 30-day option to purchase up to 2,250,000 additional ordinary shares. The net proceeds will be used to fund clinical development of pipeline candidates, including vilobelimab and INF904, and for general corporate purposes. Guggenheim Securities acted as book-running manager, with H.C. Wainwright & Co. and Lucid Capital Markets as co-lead managers.

Infinitum has launched a new blockchain ecosystem designed to bridge traditional finance (TradFi) and decentralized finance (DeFi). The platform, developed in partnership with financial systems leader Lusis, focuses on post-quantum security and asset tokenization.

According to a 2023 Bank of America report, asset tokenization is expected to represent 10% of global GDP by 2030. The ecosystem addresses critical challenges in modern finance, including scalability, regulatory compliance, and security concerns related to quantum computing advancements.

The project features Infinitum Labs, a dedicated research hub co-founded with Lusis, leveraging expertise in financial systems, cryptography, AI integration, and quantum computing. The platform implements post-quantum resilient systems and AI-driven fraud prevention to protect digital assets from potential quantum computing threats.